H Mitsuya
Overview
Explore the profile of H Mitsuya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
352
Citations
4845
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ueno N, Nishimura N, Ueno S, Endo S, Tatetsu H, Hirata S, et al.
Oncogene
. 2017 Apr;
36(31):4481-4497.
PMID: 28368411
We previously reported that PU.1 is downregulated in the majority of myeloma cell lines and primary myeloma cells of certain myeloma patients, and conditional expression of PU.1 in such myeloma...
2.
Nishimura Y, Ito H, Fujii S, Tabata H, Tokano Y, Chen Y, et al.
Mod Rheumatol
. 2014 Jan;
11(2):103-12.
PMID: 24383685
Abstract It is well known that individuals who are positive for particular HLA class II alleles show a high risk of developing autoimmune diseases. HLA class II molecules expressed on...
3.
Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H, et al.
Br J Cancer
. 2013 Jan;
108(1):170-8.
PMID: 23321518
Background: Cancer cells utilise the glycolytic pathway even when adequate oxygen is present, a phenomenon known as the Warburg effect. We examined whether this system is operative in multiple myeloma...
4.
Michailidis E, Singh K, Ryan E, Hachiya A, Ong Y, Kirby K, et al.
Cell Mol Biol (Noisy-le-grand)
. 2013 Jan;
58(1):187-95.
PMID: 23273211
4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a highly potent inhibitor of HIV-1 reverse transcriptase (RT). We have previously shown that its exceptional antiviral activity stems from a unique mechanism of action that is...
5.
Kirby K, Singh K, Michailidis E, Marchand B, Kodama E, Ashida N, et al.
Cell Mol Biol (Noisy-le-grand)
. 2011 Mar;
57(1):40-6.
PMID: 21366961
4' Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is the most potent inhibitor of HIV reverse transcriptase (RT). We have recently named EFdA a Translocation Defective RT Inhibitor (TDRTI) because after its incorporation in the...
6.
Ueno S, Tatetsu H, Hata H, Iino T, Niiro H, Akashi K, et al.
Oncogene
. 2009 Sep;
28(46):4116-25.
PMID: 19749795
We earlier reported that PU.1 was downregulated in myeloma cell lines and myeloma cells in a subset of myeloma patients, and that conditional PU.1 expression in PU.1-negative myeloma cell lines,...
7.
Richman D, Johnson V, Mayers D, Shirasaka T, OBRIEN M, Mitsuya H
Curr Protoc Immunol
. 2008 Apr;
Chapter 12:Unit 12.9.
PMID: 18432713
This unit presents an assay that has proven useful as an initial screening test is an HIV cytopathic effect (CPE) inhibition assay in which immortalized T cell lines (e.g., ATH8...
8.
Omata N, Murata T, Takamatsu S, Maruoka N, Mitsuya H, Yonekura Y, et al.
Bipolar Disord
. 2008 Apr;
10(3):360-8.
PMID: 18402624
Objectives: We evaluated the neuroprotective effect of chronically or acutely administered lithium against hypoxia in several brain regions. Furthermore, we investigated the contribution of brain-derived neurotrophic factor (BDNF), nerve growth...
9.
Yin P, Das D, Mitsuya H
Cell Mol Life Sci
. 2006 May;
63(15):1706-24.
PMID: 16715409
There are 20 available drugs for the treatment of human immunodeficiency virus (HIV) infection. With a single exception, all of these drugs inhibit either HIV reverse transcriptase or protease. Reverse...
10.
Sonoki T, Iwanaga E, Mitsuya H, Asou N
Leukemia
. 2005 Sep;
19(11):2009-10.
PMID: 16151463
No abstract available.